Satellos Bioscience (MSLE) Common Equity (2023 - 2026)

Satellos Bioscience (MSLE) has 4 years of Common Equity data on file, last reported at $70.7 million in Q1 2026.

• On a quarterly basis, Common Equity changed N/A year-over-year to $70.7 million in Q1 2026; TTM through Mar 2026 was $70.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $27.8 million, down 41.09% from the prior year.
• Common Equity for Q1 2026 stood at $70.7 million, up from $27.8 million in the prior quarter.
• Over the last five years, Common Equity for MSLE reached as high as $70.7 million in Q1 2026 and fell as low as $27.8 million in Q4 2025.
• Historically, Common Equity has averaged $44.2 million across 4 years, with a median of $39.2 million in 2023.
• Across the five-year window, Common Equity soared 62.6% in 2024 and sank 42.81% in 2025, its largest moves.
• Year by year, Common Equity stood at $29.9 million in 2023, then surged by 62.6% to $48.6 million in 2024, then sank by 42.81% to $27.8 million in 2025, then surged by 154.33% to $70.7 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $70.7 million in Q1 2026, $27.8 million in Q4 2025, and $48.6 million in Q4 2024.